Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists.
Relugolix
androgen-deprivation therapy
novel drugs
prostate cancer
Journal
Arab journal of urology
ISSN: 2090-598X
Titre abrégé: Arab J Urol
Pays: United States
ID NLM: 101562480
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
9
12
2021
pubmed:
10
12
2021
medline:
10
12
2021
Statut:
epublish
Résumé
Androgen-deprivation therapy (ADT) is the cornerstone of metastatic prostate cancer treatment. ADT can be achieved through surgical castration, or it may be induced either by gonadotrophin-releasing hormone (GnRH) agonists or GnRH antagonists. GnRH antagonists provide a more rapid castration alongside with a safer profile regarding adverse events. Degarelix is the sole GnRH antagonist used in clinical practice. Injection site reactions are the commonest adverse events related to the use of degarelix. Relugolix, a novel molecule, represents the first orally administered United States Food and Drug Administration approved GnRH antagonist, with clinical efficacy equal to that of the established ADT regimens. The main advantages of relugolix are the avoidance of the injection site reactions of GnRH antagonists such as degarelix alongside its patient-friendly oral administration. The aim of the present review article is to present novel data regarding the role of relugolix as ADT for the treatment of prostate cancer.
Identifiants
pubmed: 34881062
doi: 10.1080/2090598X.2021.1994231
pii: 1994231
pmc: PMC8648026
doi:
Types de publication
Journal Article
Langues
eng
Pagination
460-463Informations de copyright
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the author(s).
Références
Expert Opin Pharmacother. 2017 Jun;18(8):825-832
pubmed: 28480768
Eur Urol. 2021 Jan;79(1):44-53
pubmed: 32605859
Expert Rev Pharmacoecon Outcomes Res. 2017 Oct;17(5):481-488
pubmed: 28870102
Cancer Med. 2019 Oct;8(13):5891-5902
pubmed: 31429205
J Med Chem. 2011 Jul 28;54(14):4998-5012
pubmed: 21657270
J Urol. 2011 Sep;186(3):889-97
pubmed: 21788033
N Engl J Med. 2020 Jun 4;382(23):2187-2196
pubmed: 32469183
J BUON. 2016 Jul-Aug;21(4):787-791
pubmed: 27685897
BJU Int. 2008 Dec;102(11):1531-8
pubmed: 19035858
Eur Urol. 2004 Sep;46(3):279-83; discussion 283-4
pubmed: 15306097
Eur Heart J Cardiovasc Pharmacother. 2021 Jan 20;:
pubmed: 33470403
Eur Urol. 2014 Mar;65(3):565-73
pubmed: 24210090
Drugs. 2009 Oct 1;69(14):1967-76
pubmed: 19747011
Eur Urol. 2020 Aug;78(2):184-192
pubmed: 32273183
Eur Urol. 2014 Dec;66(6):1101-8
pubmed: 24440304
J Clin Endocrinol Metab. 2015 Dec;100(12):4579-87
pubmed: 26502357
Ther Adv Urol. 2016 Apr;8(2):75-82
pubmed: 27034720
Eur J Pharmacol. 2014 Jan 15;723:167-74
pubmed: 24333551